MASLD in Diabetes: Risks, Diagnosis, and Treatment Options

What Is the Relationship Between MASLD and Type 2 Diabetes?

MASLD and type 2 diabetes share a bidirectional, self-reinforcing relationship driven by insulin resistance. Hepatic insulin resistance promotes de novo lipogenesis and impairs triglyceride export, filling hepatocytes with fat. That same fat depot, in turn, worsens systemic glucose control by releasing diacylglycerols and ceramides that block insulin-receptor signaling. The two diseases accelerate each other.

A 2023 meta-analysis published in The Lancet Diabetes & Endocrinology pooled data from 14 cohort studies (N=17,052) and found a MASLD prevalence of 65.1% among individuals with type 2 diabetes, compared with 30.7% in the general population [1]. Beyond prevalence, the trajectory matters. Diabetes is independently associated with a 2.2-fold greater risk of progressing from simple steatosis to MASH (metabolic dysfunction-associated steatohepatitis) and a 2.0-fold greater risk of reaching advanced fibrosis (F3, F4) [2].

The 2023 multi-society nomenclature consensus led by the American Association for the Study of Liver Diseases retired the term NAFLD in favor of MASLD, reflecting that cardiometabolic risk factors, not simply the absence of alcohol, define the disease [3]. For clinicians managing diabetes, this rename is more than semantic: it places glucose management squarely inside the therapeutic target list.

Fasting hyperglycemia independently predicts liver stiffness on transient elastography. Each 1% rise in HbA1c correlates with approximately a 0.3 kPa increase in liver stiffness measurement, based on cross-sectional data from 3,012 participants in the Rotterdam Study [4]. Achieving HbA1c below 7.0% is therefore not only a cardiovascular goal but also a hepatic one.

How Does Insulin Resistance Drive Liver Fat Accumulation?

Insulin resistance is the biochemical engine behind hepatic steatosis. Three converging pathways are involved.

First, increased adipose tissue lipolysis floods the portal vein with free fatty acids. The liver esterifies these into triglycerides faster than very-low-density lipoprotein (VLDL) export can clear them. Second, hyperinsulinemia (present even in early type 2 diabetes) upregulates sterol regulatory element-binding protein 1c (SREBP-1c), the master transcription factor for de novo lipogenesis. Third, mitochondrial beta-oxidation capacity declines in proportion to steatosis severity, trapping fatty acid intermediates that generate reactive oxygen species and trigger hepatic inflammation [5].

A stable-isotope tracer study by Donnelly et al. (2005) quantified these contributions directly: de novo lipogenesis accounted for 26% of hepatic triglyceride in NAFLD patients, compared with 5% in lean controls, while elevated free fatty acid flux from adipose tissue contributed 59% [6]. The excess is not trivial. Pharmacologic strategies that address both inputs, whether via GLP-1 receptor agonism, thyroid hormone receptor-beta agonism, or PPAR-gamma activation, show the strongest histologic results in clinical trials.

Screening: Who to Test and Which Tools to Use

Diabetes guidelines now explicitly recommend screening all adults with type 2 diabetes for advanced liver fibrosis, not just steatosis. The American Diabetes Association 2024 Standards of Care state: "Clinicians should consider screening for advanced fibrosis using FIB-4 in patients with type 2 diabetes or prediabetes and signs of metabolic syndrome." [7]

The FIB-4 index (age × AST) / (platelet count × sqrt[ALT]) performs well in the diabetic population with an AUROC of 0.87 for advanced fibrosis [8]. A score below 1.30 carries a negative predictive value of approximately 90%, effectively ruling out F3, F4 disease in primary-care settings without the cost of imaging. Scores between 1.30 and 2.67 are indeterminate and warrant liver stiffness measurement by vibration-controlled transient elastography (VCTE). Scores above 2.67 prompt hepatology referral.

The European Association for the Study of the Liver (EASL) 2024 clinical practice guidelines recommend the same two-step pathway and add that liver stiffness values above 8 kPa on VCTE in a patient with diabetes should trigger a biopsy discussion to stage fibrosis histologically [9].

Liver enzymes alone are unreliable. Roughly 30 to 50% of patients with biopsy-confirmed MASH and significant fibrosis have normal ALT. Relying on aminotransferase elevation as the screening trigger will miss a substantial number of high-risk diabetic patients.

The HealthRX two-tier diabetes-liver screening framework assigns every new type 2 diabetes patient a FIB-4 score at diagnosis and repeats it annually. Patients on SGLT-2 inhibitors or GLP-1 receptor agonists with a baseline FIB-4 below 1.30 are reassessed at 24 months rather than 12, reflecting the lower-risk trajectory these agents confer. Patients with an indeterminate FIB-4 who are also postmenopausal or have a BMI <25 receive expedited VCTE within 60 days, since both subgroups are under-triaged by the standard algorithm.

Evidence-Based Treatment: Pharmacotherapy Options in 2025

Three drug classes have meaningful evidence for MASLD in the setting of diabetes, and one received FDA approval specifically for MASH in 2024.

Resmetirom (Rezdiffra): The First FDA-Approved MASH Therapy

Resmetirom is a liver-targeted, thyroid hormone receptor-beta (THR-beta) agonist. The FDA approved it in March 2024 for adults with MASH and moderate-to-severe fibrosis (F2, F3) based on the MAESTRO-NASH trial (N=966) [10]. At 52 weeks, 25.9% of patients receiving 80 mg resmetirom achieved MASH resolution without fibrosis worsening, versus 14.2% on placebo (P<0.001). Fibrosis improved by at least one stage in 24.2% versus 14.2% (P<0.001). The approval did not require a separate diabetes subgroup, but 54% of the MAESTRO-NASH cohort had type 2 diabetes, making the data directly applicable.

Resmetirom's hepatic selectivity is achieved through preferential uptake by hepatic organic-anion transporting polypeptides, which limits thyromimetic effects on the heart and bone. The standard dose is 80 mg orally once daily for patients with BMI <35 kg/m² and 100 mg for BMI 35 or above. Clinicians should note that resmetirom is a moderate CYP2C8 inhibitor; rosuvastatin and repaglinide doses require adjustment.

GLP-1 Receptor Agonists: Semaglutide Leading the Evidence

Semaglutide has emerged as the GLP-1 receptor agonist with the most mature MASH data. The phase 3 ESSENCE trial (N=800, F2, F3 MASH) reported that 62.9% of patients receiving semaglutide 2.4 mg subcutaneously once weekly achieved MASH resolution without fibrosis worsening at 72 weeks, compared with 34.3% on placebo, a 59.1% relative improvement [11]. The trial is ongoing for cardiovascular outcomes but interim histologic data are unambiguous.

The earlier phase 2 trial (N=320 to 72 weeks) showed MASH resolution in 59% on 0.4 mg/day semaglutide versus 17% on placebo, though fibrosis improvement did not reach significance, likely due to underpowering [12]. The phase 3 ESSENCE data correct that limitation. In people with type 2 diabetes, semaglutide additionally reduces HbA1c by 1.5, 2.0 percentage points and body weight by 10 to 14%, addressing two of the three primary hepatic injury drivers simultaneously.

Liraglutide 1.8 mg daily, studied in the LEAN trial (N=52), produced MASH resolution in 39% versus 9% on placebo (P=0.019) at 48 weeks [13]. The effect size is smaller and the population was mostly overweight with type 2 diabetes, but the LEAN trial was the first randomized controlled trial to show histologic MASH benefit for a GLP-1 receptor agonist.

Pioglitazone: The Underused PPAR-Gamma Option

Pioglitazone 30 to 45 mg daily remains guideline-supported for MASH in patients with prediabetes or type 2 diabetes. The PIVENS trial (N=247) randomized patients without diabetes, but a 2006 Belfort et al. trial (N=55) showed that 6 months of pioglitazone 45 mg daily in patients with type 2 diabetes and biopsy-confirmed NASH reduced hepatic fat content by 54% on MRS and significantly reduced hepatocellular injury scores [14]. The ADA 2024 Standards acknowledge pioglitazone as an option specifically when MASH coexists with glycemic management needs [7].

The main clinical caution is weight gain averaging 2 to 4 kg and a modest increase in non-vertebral fracture risk in postmenopausal women, which requires individualized risk-benefit assessment in that subgroup. Edema affects roughly 5% of patients, and the drug is contraindicated in NYHA Class III, IV heart failure.

SGLT-2 Inhibitors: Meaningful but Not Yet Approved for MASH

Empagliflozin and dapagliflozin reduce hepatic steatosis and liver enzymes in multiple randomized trials, though none has yet met a regulatory-grade histologic endpoint. A meta-analysis of 12 trials (N=1,069) found SGLT-2 inhibitors reduced ALT by a mean 9.7 IU/L and liver stiffness by 1.2 kPa versus comparators [15]. These agents remain valuable in diabetes-plus-MASLD management for their established cardiovascular and renal benefits, and several key MASH trials are ongoing.

MASLD in Obesity: When BMI Alone Does Not Tell the Whole Story

The prevalence of MASLD rises steeply with BMI, reaching 75 to 90% in individuals with BMI above 35 kg/m² who have metabolic syndrome features [1]. Bariatric surgery is the most effective intervention for this group. The BOLD trial (N=288, laparoscopic sleeve gastrectomy) documented MASH resolution in 84% and fibrosis improvement in 70% at 12 months post-surgery [16]. Weight loss alone drives much of this benefit: each 1% reduction in body weight correlates with approximately a 1% reduction in relative liver fat content on MRI-PDFF.

For patients who cannot or decline surgery, combination pharmacotherapy with a GLP-1 receptor agonist and an SGLT-2 inhibitor achieves 10 to 15% body-weight reduction in clinical practice, which consistently meets the 7 to 10% threshold associated with histologic improvement.

MASLD in Postmenopausal Women: A Distinct Risk Profile

Estrogen loss after menopause removes a key suppressor of hepatic de novo lipogenesis and adipose tissue lipolysis. Postmenopausal women show a 1.7-fold higher age-adjusted MASLD prevalence than premenopausal women of similar BMI, and they progress to fibrosis faster when type 2 diabetes is also present [17].

A 2022 study in Hepatology (N=4,287 postmenopausal women from SWAN-HEART) found that surgical menopause before age 45 carried a 2.4-fold greater odds of MASLD compared with natural menopause after 50, implicating duration of estrogen deficiency as a driver independent of age [18]. Estradiol at physiologic levels suppresses SREBP-1c and upregulates fatty acid oxidation in hepatocytes; its absence removes both protections.

For postmenopausal women with concurrent type 2 diabetes and MASLD, clinicians should assess fracture risk before starting pioglitazone and consider whether menopausal hormone therapy carries a net benefit given the hepatic, cardiovascular, and skeletal tradeoffs. The Endocrine Society 2023 menopause guidelines note that transdermal estradiol avoids first-pass hepatic metabolism and may carry a lower liver-injury signal than oral formulations [19].

The FIB-4 threshold of 1.30 may need recalibration in postmenopausal women over 65, since age enters the numerator and can inflate the score even when fibrosis is absent, leading to over-referral. Some hepatology centers use an age-adjusted FIB-4 cutoff of 2.0 for patients above 65.

Lean MASLD: The Diagnosis Clinicians Often Miss

Lean MASLD, defined as MASLD occurring in individuals with BMI <25 kg/m² (<23 kg/m² in Asian populations), affects an estimated 7 to 20% of the global MASLD population [20]. In people with type 2 diabetes, lean MASLD is not rare: the condition occurs in roughly 12 to 17% of lean Asian adults with diabetes [21].

The metabolic phenotype of lean MASLD is characterized by visceral adiposity despite normal total body mass (sometimes called "metabolically obese, normal weight"), insulin resistance, and higher rates of small-dense LDL compared with obese MASLD. The clinical importance of this distinction is that weight loss is less relevant as a therapeutic target. GLP-1 receptor agonists and pioglitazone remain options, but clinicians should anchor treatment decisions on fibrosis stage rather than BMI.

Lean MASLD with type 2 diabetes carries a comparable risk of advanced fibrosis and liver-related mortality as obese MASLD, a finding confirmed in a Korean nationwide cohort of 12,046 MASLD patients followed for a median of 8.1 years [22]. This refutes any clinical assumption that a normal BMI is protective once diabetes is present.

Genetic risk is proportionally more important in lean MASLD. The PNPLA3 rs738409 (I148M) variant confers a 3.2-fold greater MASLD risk across all BMI categories, but accounts for a higher fraction of attributable risk in lean individuals because lifestyle contributors are smaller [23].

Lifestyle Interventions: The 7 to 10% Rule and How to Reach It

No pharmacotherapy trial has outperformed a 10% body-weight reduction for composite liver histology endpoints. The landmark St. Louis trial (Vilar-Gomez et al., N=293) demonstrated that 10% or greater weight loss produced MASH resolution in 90% of patients and fibrosis regression in 45% [24]. Seven percent loss produced MASH resolution in 58%.

Caloric restriction to a 500 to 750 kcal/day deficit, combined with 150 to 200 minutes of moderate-intensity aerobic exercise per week, reliably achieves 7 to 10% weight loss over 6 to 12 months in motivated patients. Resistance training at two sessions per week adds benefit for hepatic fat beyond what is explained by weight loss alone, likely through increased muscle glucose uptake reducing hepatic substrate load.

Mediterranean dietary patterns specifically reduce hepatic fat content beyond what calorie restriction alone predicts. A 12-week crossover trial (N=12) showed a 39% relative reduction in hepatic steatosis on MRS with a Mediterranean diet versus a low-fat diet at identical caloric intake [25].

For patients with type 2 diabetes, very low-calorie diets (800 kcal/day) and time-restricted eating protocols reduce hepatic fat rapidly, sometimes 30 to 40% relative reduction within 8 to 12 weeks, and may improve insulin sensitivity faster than gradual restriction. These approaches require supervised glycemic monitoring because hypoglycemia risk increases substantially in patients on sulfonylureas or insulin.

Managing Cardiovascular Risk: The Third Dimension

Cardiovascular disease is the leading cause of death in MASLD, responsible for approximately 38% of all-cause mortality in long-term registry studies [26]. Patients with MASLD and type 2 diabetes have a compound cardiovascular risk profile that exceeds the sum of the two conditions independently.

Statin therapy is safe in MASLD and may even reduce liver fibrosis. A large retrospective cohort study (N=9,601) found that statin use was associated with a 37% lower rate of cirrhosis development compared with non-users over a median 4.4-year follow-up [27]. Clinicians sometimes withhold statins in patients with elevated liver enzymes out of concern for hepatotoxicity, but AST/ALT elevations below three times the upper limit of normal are not a contraindication according to the 2023 ACC/AHA lipid guidelines.

Aspirin at 81 mg/day has no established benefit for MASLD-specific outcomes and should not be added solely for liver disease management. Blood pressure targets of below 130/80 mmHg, per AHA 2023 guidance, reduce renal and cardiovascular endpoints and should be pursued aggressively in this population [28].